On 16 July 2024, Sandoz announced the Canadian launch of Wyost® (denosumab), biosimilar to Amgen’s Xgeva®. Wyost® is available as a 120 mg subcutaneous injection for use every four weeks.
Wyost® was the first denosumab biosimilar approved in Canada in March 2024 for all Xgeva® indications, including the prevention of bone fractures in bone metastatic cancers and treatment of bone giant cell tumours in adults. This followed the Canadian approval of Sandoz’s Jubbonti®, biosimilar to Amgen’s Prolia® (denosumab) in February 2024 for osteoporosis and increasing bone mass.
Sandoz’s Wyost® and Jubbonti® were the first denosumab biosimilars approved in the US in March 2024. Following the April 2024 resolution of US BPCI proceedings commenced by Amgen against Sandoz in May 2023, Jubbonti® and Wyost® are expected to launch in the US from 31 May 2025.